European Journal of Surgical Oncology (EJSO) 2009-01-01

Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study

R. Greil, M. Moik, R. Reitsamer, S. Ressler, M. Stoll, K. Namberger, C. Menzel, B. Mlineritsch, R. Greil, M. Moik, R. Reitsamer, S. Ressler, M. Stoll, K. Namberger, C. Menzel, B. Mlineritsch

Index: Eur. J. Surg. Oncol. 35(10) , 1048-54, (2009)

Full Text: HTML

Abstract

Purpose To evaluate the triplet combination of bevacizumab, capecitabine and docetaxel (XTA) as neoadjuvant therapy for breast cancer.